These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 31556015

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
    Wang J, Yan L, Ai P, He Y, Guan H, Wei Z, He L, Mu X, Liu Y, Peng X.
    Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
    [Abstract] [Full Text] [Related]

  • 3. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.
    J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
    [Abstract] [Full Text] [Related]

  • 4. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC.
    JAMA Oncol; 2023 Jul 01; 9(7):919-927. PubMed ID: 37200021
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM.
    Neuro Oncol; 2017 Feb 01; 19(2):242-251. PubMed ID: 27571885
    [Abstract] [Full Text] [Related]

  • 6. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
    Steidl E, Filipski K, Zeiner PS, Wagner M, Fokas E, Forster MT, Ronellenfitsch MW, Divé I, Steinbach JP, Harter PN, Bähr O.
    J Cancer Res Clin Oncol; 2021 Aug 01; 147(8):2373-2383. PubMed ID: 33538917
    [Abstract] [Full Text] [Related]

  • 7. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.
    Cancer Med; 2020 Jan 01; 9(1):3-11. PubMed ID: 31701682
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S, Chatterjee A, Gupta T, Panda P, Moiyadi A, Epari S, Patil V, Krishnatry R, Goda JS, Jalali R.
    World Neurosurg; 2021 Oct 01; 154():e176-e184. PubMed ID: 34245877
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM.
    J Neurooncol; 2015 Mar 01; 122(1):111-9. PubMed ID: 25534576
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
    Vogelbaum MA, Hu C, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, Souhami L, Mehta MP.
    J Neurooncol; 2015 Sep 01; 124(3):413-20. PubMed ID: 26088460
    [Abstract] [Full Text] [Related]

  • 12. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 13. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
    Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH, Nam DH, Kim SH, Yoo H, Hong YK, Kim EY, Lee DE, Joo J, Kim YJ, Choe G, Choi BS, Kang SG, Kim JH, Kim CY.
    Cancer Res Treat; 2020 Apr 01; 52(2):505-515. PubMed ID: 31671938
    [Abstract] [Full Text] [Related]

  • 14. 11C-Methionine Integrated PET/MRI-Based Texture Analysis Features May Have a Potential Ability to Distinguish Oligodendroglioma (IDH-Mutant and 1p/19q-Codeleted) From Varied Gliomas.
    Zhao K, Yu P, Xue Z, Liu J, Yao A, Zhao Y, Yang F, Tian J, Xu B.
    Acad Radiol; 2020 Jul 01; 27(7):e159-e167. PubMed ID: 31607471
    [Abstract] [Full Text] [Related]

  • 15. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC, Park DYJ, Yang K, Leyrer CM, Wei W, Jia X, Varra V, Yu JS, Chao ST, Balagamwala EH, Suh JH, Vogelbaum MA, Barnett GH, Prayson RA, Stevens GHJ, Peereboom DM, Ahluwalia MS, Murphy ES.
    Int J Radiat Oncol Biol Phys; 2019 Dec 01; 105(5):1106-1112. PubMed ID: 31461674
    [Abstract] [Full Text] [Related]

  • 16. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
    Iwadate Y, Matsutani T, Hara A, Hirono S, Ikegami S, Kobayashi M, Ito D, Kawauchi D, Horiguchi K, Tamiya A, Higuchi Y.
    J Neurooncol; 2019 Jan 01; 141(1):205-211. PubMed ID: 30565028
    [Abstract] [Full Text] [Related]

  • 17. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.
    J Neurooncol; 2015 Sep 01; 124(2):197-205. PubMed ID: 26033545
    [Abstract] [Full Text] [Related]

  • 18. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
    Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.
    Neuro Oncol; 2017 Oct 01; 19(10):1380-1390. PubMed ID: 28472509
    [Abstract] [Full Text] [Related]

  • 19. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D, For POLA Network.
    Acta Neuropathol; 2016 Oct 01; 132(4):625-34. PubMed ID: 27573687
    [Abstract] [Full Text] [Related]

  • 20. Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
    Khurana R, Rath S, Singh HB, Rastogi M, Nanda SS, Chauhan A, Kaif M, Hussain N.
    Asian Pac J Cancer Prev; 2020 Mar 01; 21(3):755-760. PubMed ID: 32212804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.